Aimmune Therapeutics Inc. (AIMT)

19.90
0.33 1.70
NASDAQ : Health Technology
Prev Close 19.57
Open 19.62
Day Low/High 19.60 / 19.95
52 Wk Low/High 19.25 / 36.12
Volume 52.18K
Avg Volume 482.20K
Exchange NASDAQ
Shares Outstanding 62.49M
Market Cap 1.25B
EPS -3.70
P/E Ratio N/A
Div & Yield N.A. (N.A)
Aimmune Therapeutics' Pivotal Phase 3 PALISADE Trial Of AR101 Meets Primary Endpoint In Patients With Peanut Allergy

Aimmune Therapeutics' Pivotal Phase 3 PALISADE Trial Of AR101 Meets Primary Endpoint In Patients With Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its pivotal Phase 3 PALISADE efficacy trial of AR101 met the...

Aimmune Therapeutics Expands Scientific Advisory Board With Appointments Of George Du Toit, M.B., B.Ch., And Wayne Shreffler, M.D., Ph.D.

Aimmune Therapeutics Expands Scientific Advisory Board With Appointments Of George Du Toit, M.B., B.Ch., And Wayne Shreffler, M.D., Ph.D.

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the expansion of its Scientific Advisory Board with the...

Aimmune Therapeutics Announces Presentations At 2018 AAAAI-WAO Joint Congress

Aimmune Therapeutics Announces Presentations At 2018 AAAAI-WAO Joint Congress

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data during a late-breaking oral abstract...

There Is Still Plenty of Strong, Tradable Action

There Is Still Plenty of Strong, Tradable Action

This market may be extended by just about any measure, but that doesn't mean you should be fighting it.

How Trading Notes Can Increase Your Profits

How Trading Notes Can Increase Your Profits

Inertia is your biggest enemy in this market.

You Can't Reason With a Steamroller

You Can't Reason With a Steamroller

The momentum is crushing everything in its way.

Aimmune Therapeutics Broadens And Extends Supply Agreement With Golden Peanut And Tree Nuts For AR101 For Peanut Allergy

Aimmune Therapeutics Broadens And Extends Supply Agreement With Golden Peanut And Tree Nuts For AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced an expansion and extension of its exclusive supply agreement with...

Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 PALISADE Trial Of AR101 For Peanut Allergy

Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data From Pivotal Phase 3 PALISADE Trial Of AR101 For Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced its outlook for the coming year, including its plans to report...

Aimmune Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Aimmune Therapeutics To Present At The 36th Annual J.P. Morgan Healthcare Conference

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Stephen Dilly, M.

Volume Slows Ahead of Christmas Holiday

Volume Slows Ahead of Christmas Holiday

Breadth is slightly negative as markets ease into 3-day weekend.

Blockchain Will Be a Top Investing Theme in 2018

Blockchain Will Be a Top Investing Theme in 2018

The applications for this distributed ledger technology are endless.

Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling

Moore Loss Won't Stop Tax Bill; Bitcoin Plays Are Bubbling

The republican loss in the Alabama special election for U.S. senate had only a brief imapct on stock futures.

Aimmune Therapeutics To Participate In The BMO Capital Markets 2017 Prescriptions For Success Healthcare Conference On December 14

Aimmune Therapeutics To Participate In The BMO Capital Markets 2017 Prescriptions For Success Healthcare Conference On December 14

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside...

Aimmune Therapeutics To Host Investor Symposium On Peanut Allergy Treatment With Leading Expert Allergists On Friday, December 1

Aimmune Therapeutics To Host Investor Symposium On Peanut Allergy Treatment With Leading Expert Allergists On Friday, December 1

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017.

As Dip Buyers Jump in, Stay Focused on Stock Picking

As Dip Buyers Jump in, Stay Focused on Stock Picking

Small-caps are lagging and breadth is negative, but the computer algorithms are very impressive.

Aimmune Therapeutics Announces Third Quarter 2017 Financial Results And Planned Retirement Of CEO By The End Of 2018

Aimmune Therapeutics Announces Third Quarter 2017 Financial Results And Planned Retirement Of CEO By The End Of 2018

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2017.

Selling Subsides, but Market's Still a Mess

Selling Subsides, but Market's Still a Mess

Facebook, Alibaba sell off on very good reports.

Aimmune Therapeutics To Participate In Four Investor Conferences In November

Aimmune Therapeutics To Participate In Four Investor Conferences In November

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in...

Aimmune Therapeutics Announces Publication In The Journal Of Allergy And Clinical Immunology: In Practice Of Positive AR101 Data From ARC001 Phase 2 Clinical Trial

Aimmune Therapeutics Announces Publication In The Journal Of Allergy And Clinical Immunology: In Practice Of Positive AR101 Data From ARC001 Phase 2 Clinical Trial

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the online publication of positive data from its ARC001 Phase 2...

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

Alexion Pops After Securing FDA Nod for Myasthenia Gravis Drug -- Biotech Movers

The New Haven, Conn.-based firm said Monday it has secured approval from the U.S. Food and Drug Administration for Soliris (eculizumab) as a treatment for adults with generalized myasthenia gravis (gMG) that are anti-acetylcholine receptor (AChR) antibody-positive.

The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

The Hartford, Aetna Ink Tie-Up; All Eyes on Peanut Allergies -- ICYMI

Here's what you need to know now for Monday, Oct. 23.

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

DBV Shares Fall After Phase 3 Data on Peanut Allergy Treatment -- Biotech Movers

The Montrouge, France-based firm on Friday unveiled top-line results from its Phase 3 study of a peanut allergy treatment. The study, dubbed Pepites, evaluated Viaskin Peanut in children four to 11 years old.

Aimmune Therapeutics To Present Data On Peanut Allergy At ACAAI And PAAM Medical Meetings

Aimmune Therapeutics To Present Data On Peanut Allergy At ACAAI And PAAM Medical Meetings

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data on peanut allergy during poster sessions...

Aimmune Therapeutics Announces Clinical Collaboration To Study AR101 With Regeneron And Sanofi's Dupilumab For Peanut Allergy

Aimmune Therapeutics Announces Clinical Collaboration To Study AR101 With Regeneron And Sanofi's Dupilumab For Peanut Allergy

Aimmune Therapeutics, Inc. (NASDAQ:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced a clinical collaboration with Regeneron and its strategic alliance...

Interesting AIMT Put And Call Options For November 17th

Interesting AIMT Put And Call Options For November 17th

Investors in Aimmune Therapeutics Inc saw new options begin trading this week, for the November 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AIMT options chain for the new November 17th contracts and identified one put and one call contract of particular interest.

Aimmune Therapeutics To Participate In Three Investor Conferences In September

Aimmune Therapeutics To Participate In Three Investor Conferences In September

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will be presenting at...

Aimmune Therapeutics To Present At The 2017 Wedbush PacGrow Healthcare Conference On Wednesday, August 16th

Aimmune Therapeutics To Present At The 2017 Wedbush PacGrow Healthcare Conference On Wednesday, August 16th

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview at the 2017 Wedbush...

Aimmune Therapeutics Announces Second Quarter 2017 Financial Results

Aimmune Therapeutics Announces Second Quarter 2017 Financial Results

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2017.

Aimmune Therapeutics' Investigational Treatment For Peanut Allergy Featured In Science Translational Medicine Publication On Discovery Of New TH2 Cell Subset Specific To Allergy

Aimmune Therapeutics' Investigational Treatment For Peanut Allergy Featured In Science Translational Medicine Publication On Discovery Of New TH2 Cell Subset Specific To Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its investigational treatment for peanut allergy, AR101, was highlighted...

Aimmune Therapeutics Enrolls First Patient In ARTEMIS (ARC010) European Phase 3 Clinical Trial Of AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics Enrolls First Patient In ARTEMIS (ARC010) European Phase 3 Clinical Trial Of AR101 For The Treatment Of Peanut Allergy

Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the enrollment of its first patient in the European Phase 3 ARTEMIS (ARC010) clinical trial of AR101 for treatment of peanut allergy.